Clinical trials: Prostate Cancer Stage
CLL, Solid Tumor, Adult
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
The goal of this clinical trial is to test the safety and preliminary efficacy of a new drug, KLS-1, in adults with different types of solid tumors and chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06506643
- Testing
- Zinc-64 Aspartate
- Where
- 2 sites in Ukraine
- Volunteers
- 36 people
- Sponsor
- Vector Vitale LLC
Prostate Cancer Patients
The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
- Trial name
- NCT04676035
- Testing
- Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hormone-refractory Prostate Cancer
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
This study is a phase I study of a cell based prostate cancer therapy, Autologous Lymphoid Effector Cells Specific Against Tumor-cells (ALECSAT).
- Trial name
- ALECSAT (NCT01422850)
- Testing
- ALECSAT
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- CytoVac A/S
Prostate Cancer
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with…
- Trial name
- NCT00314782
- Testing
- ZD4054 (Zibotentan), Docetaxel
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and androgen receptor pathway inhibitor (ARPI) therapy work in participants with prostate gland cancer which has spread to the bone and…
- Trial name
- RADIANT (NCT04597125)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), ARPI therapy
- Where
- 117 sites in Australia, Austria and 17 more
- Volunteers
- 654 people
- Sponsor
- Bayer
Prostate Cancer
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who…
- Trial name
- NCT02445976
- Testing
- Seviteronel: given orally once daily in 28-day cycles
- Where
- 21 sites in United States
- Volunteers
- 197 people
- Sponsor
- Innocrin Pharmaceutical
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\&T) in combination with Olaparib in participants with mCRPC.
- Trial name
- NCT06909825
- Testing
- FPI-2265, Olaparib
- Where
- 4 sites in Australia
- Volunteers
- 85 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Metastatic Castration-resistant Prostate Cancer
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
- Trial name
- VECTRA-01 (NCT07611110)
- Testing
- Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone
- Where
- 151 sites in United States, Australia and 22 more
- Volunteers
- 670 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms, Castration-Resistant
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate…
- Trial name
- NCT02204072
- Testing
- BI 836845, Enzalutamide
- Where
- 27 sites in United States, Hong Kong and 6 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Prostatic Adenoma
Teverelix Evaluated in Advanced Prostate Cancer
The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer
- Trial name
- TEACh (NCT04693507)
- Testing
- teverelix TFA 120 mg, teverelix TFA 180 mg
- Where
- 4 sites in Lithuania
- Volunteers
- 50 people
- Sponsor
- Antev Ltd.
Prostate Cancer, Prostatic Neoplasms
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
To determine: Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate cancer. Group A - subjects who have not previously received chemotherapy Group B - sujects who have received prior chemotherapy…
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Cancer of the Prostate
- Trial name
- IPI-504-04 (NCT00564928)
- Testing
- IPI-504
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Metastatic Cancer, Neoplasm, Prostate
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC.
- Conditions
- Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
- Trial name
- NCT05422911
- Testing
- Abiraterone acetate, Apalutamide, Enzalutamide
- Where
- 12 sites in United States
- Volunteers
- 192 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Prostate Cancer, Castration-resistant Prostate Cancer
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.
- Trial name
- NCT03741712
- Testing
- SHR3680, SHR2554
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostatic Neoplasms
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic…
- Trial name
- PSMAfore (NCT04689828)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 72 sites in United States, Austria and 12 more
- Volunteers
- 469 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Prostate Cancer
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
- Trial name
- NCT01591122
- Testing
- Abiraterone acetate and prednisone
- Where
- 22 sites in China, Malaysia and 2 more
- Volunteers
- 313 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors, Adenocarcinoma of the Prostate
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
The purpose of this study is to evaluate the safety and tolerability of alisertib in combination with docetaxel as a treatment for participants with advanced solid tumors, including castration-resistant prostate cancer, who were…
- Trial name
- NCT01094288
- Testing
- Alisertib, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Adenocarcinoma of the Prostate
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
This open label, dose escalating study is a phase I/IIa first in man study designed to evaluate the safety and tolerability of intratumoral administration of a novel oncolytic adenovirus (ORCA-010) in treating diagnosed treatment…
- Trial name
- NCT04097002
- Testing
- ORCA-010
- Where
- 5 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Orca Therapeutics B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.